Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study

Vincenzo Belcastro, Cinzia Costa, Francesca Galletti, Alessia Autuori, Laura Pierguidi, Francesco Pisani, Paolo Calabresi, Lucilla Parnetti

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Levetiracetam (LEV) monotherapy was investigated in 35 patients (pts) (16M/19F, 71.9 ± 7.3 years of age) with late-onset post-stroke seizures (i.e. seizures occurring at least 2 weeks after an ischemic stroke) in a prospective open-label study. Overall, 27 pts (77.1%) achieved a condition of seizure freedom (defined as 1 year without seizures): 19 (54.3%) at a daily LEV dose of 1000 mg, 7 (20.0%) at 1500 mg, 1 (2.8%) at 2000 mg. Four pts (11.4%) discontinued the drug because of intolerable side effects (drowsiness associated to gait disturbance in 1 pt, and aggressive behaviour in the remaining 3 pts); 3 pts were unresponsive at a dose of 3000 mg, and 1 pt was lost at follow-up. These observations suggest that LEV exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke seizures.

Original languageEnglish
Pages (from-to)223-226
Number of pages4
JournalEpilepsy Research
Volume82
Issue number2-3
DOIs
Publication statusPublished - Dec 2008

Fingerprint

etiracetam
Observational Studies
Seizures
Stroke
Prospective Studies
Sleep Stages
Gait
Pharmaceutical Preparations
Safety

Keywords

  • Antiepileptic drugs
  • Ischemic stroke
  • Late-onset seizures
  • Levetiracetam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Belcastro, V., Costa, C., Galletti, F., Autuori, A., Pierguidi, L., Pisani, F., ... Parnetti, L. (2008). Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study. Epilepsy Research, 82(2-3), 223-226. https://doi.org/10.1016/j.eplepsyres.2008.08.008

Levetiracetam in newly diagnosed late-onset post-stroke seizures : A prospective observational study. / Belcastro, Vincenzo; Costa, Cinzia; Galletti, Francesca; Autuori, Alessia; Pierguidi, Laura; Pisani, Francesco; Calabresi, Paolo; Parnetti, Lucilla.

In: Epilepsy Research, Vol. 82, No. 2-3, 12.2008, p. 223-226.

Research output: Contribution to journalArticle

Belcastro, V, Costa, C, Galletti, F, Autuori, A, Pierguidi, L, Pisani, F, Calabresi, P & Parnetti, L 2008, 'Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study', Epilepsy Research, vol. 82, no. 2-3, pp. 223-226. https://doi.org/10.1016/j.eplepsyres.2008.08.008
Belcastro, Vincenzo ; Costa, Cinzia ; Galletti, Francesca ; Autuori, Alessia ; Pierguidi, Laura ; Pisani, Francesco ; Calabresi, Paolo ; Parnetti, Lucilla. / Levetiracetam in newly diagnosed late-onset post-stroke seizures : A prospective observational study. In: Epilepsy Research. 2008 ; Vol. 82, No. 2-3. pp. 223-226.
@article{46cf032f9d0c4694be4af582cc5b758a,
title = "Levetiracetam in newly diagnosed late-onset post-stroke seizures: A prospective observational study",
abstract = "Levetiracetam (LEV) monotherapy was investigated in 35 patients (pts) (16M/19F, 71.9 ± 7.3 years of age) with late-onset post-stroke seizures (i.e. seizures occurring at least 2 weeks after an ischemic stroke) in a prospective open-label study. Overall, 27 pts (77.1{\%}) achieved a condition of seizure freedom (defined as 1 year without seizures): 19 (54.3{\%}) at a daily LEV dose of 1000 mg, 7 (20.0{\%}) at 1500 mg, 1 (2.8{\%}) at 2000 mg. Four pts (11.4{\%}) discontinued the drug because of intolerable side effects (drowsiness associated to gait disturbance in 1 pt, and aggressive behaviour in the remaining 3 pts); 3 pts were unresponsive at a dose of 3000 mg, and 1 pt was lost at follow-up. These observations suggest that LEV exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke seizures.",
keywords = "Antiepileptic drugs, Ischemic stroke, Late-onset seizures, Levetiracetam",
author = "Vincenzo Belcastro and Cinzia Costa and Francesca Galletti and Alessia Autuori and Laura Pierguidi and Francesco Pisani and Paolo Calabresi and Lucilla Parnetti",
year = "2008",
month = "12",
doi = "10.1016/j.eplepsyres.2008.08.008",
language = "English",
volume = "82",
pages = "223--226",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Levetiracetam in newly diagnosed late-onset post-stroke seizures

T2 - A prospective observational study

AU - Belcastro, Vincenzo

AU - Costa, Cinzia

AU - Galletti, Francesca

AU - Autuori, Alessia

AU - Pierguidi, Laura

AU - Pisani, Francesco

AU - Calabresi, Paolo

AU - Parnetti, Lucilla

PY - 2008/12

Y1 - 2008/12

N2 - Levetiracetam (LEV) monotherapy was investigated in 35 patients (pts) (16M/19F, 71.9 ± 7.3 years of age) with late-onset post-stroke seizures (i.e. seizures occurring at least 2 weeks after an ischemic stroke) in a prospective open-label study. Overall, 27 pts (77.1%) achieved a condition of seizure freedom (defined as 1 year without seizures): 19 (54.3%) at a daily LEV dose of 1000 mg, 7 (20.0%) at 1500 mg, 1 (2.8%) at 2000 mg. Four pts (11.4%) discontinued the drug because of intolerable side effects (drowsiness associated to gait disturbance in 1 pt, and aggressive behaviour in the remaining 3 pts); 3 pts were unresponsive at a dose of 3000 mg, and 1 pt was lost at follow-up. These observations suggest that LEV exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke seizures.

AB - Levetiracetam (LEV) monotherapy was investigated in 35 patients (pts) (16M/19F, 71.9 ± 7.3 years of age) with late-onset post-stroke seizures (i.e. seizures occurring at least 2 weeks after an ischemic stroke) in a prospective open-label study. Overall, 27 pts (77.1%) achieved a condition of seizure freedom (defined as 1 year without seizures): 19 (54.3%) at a daily LEV dose of 1000 mg, 7 (20.0%) at 1500 mg, 1 (2.8%) at 2000 mg. Four pts (11.4%) discontinued the drug because of intolerable side effects (drowsiness associated to gait disturbance in 1 pt, and aggressive behaviour in the remaining 3 pts); 3 pts were unresponsive at a dose of 3000 mg, and 1 pt was lost at follow-up. These observations suggest that LEV exhibits safety and efficacy profiles which make it an optimal candidate as a first-choice drug against post-stroke seizures.

KW - Antiepileptic drugs

KW - Ischemic stroke

KW - Late-onset seizures

KW - Levetiracetam

UR - http://www.scopus.com/inward/record.url?scp=56449130278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449130278&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2008.08.008

DO - 10.1016/j.eplepsyres.2008.08.008

M3 - Article

C2 - 18829259

AN - SCOPUS:56449130278

VL - 82

SP - 223

EP - 226

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 2-3

ER -